PT - JOURNAL ARTICLE AU - Daniel R. Morales AU - Lionel Fonkwen AU - Hedvig M. Nordeng TI - Anti-thyroid drug use during the first trimester of pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations AID - 10.1101/2020.06.10.20127233 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.10.20127233 4099 - http://medrxiv.org/content/early/2020/06/11/2020.06.10.20127233.short 4100 - http://medrxiv.org/content/early/2020/06/11/2020.06.10.20127233.full AB - Background Maternal anti-thyroid drug (ATD) use during the first trimester of pregnancy has been associated with an increased risk of birth defects in offspring. Uncertainty remains on the size of this risk and how it compares to untreated hyperthyroidism due to methodological limitations of previous studies.Methods Systematic review of MEDLINE and EMBASE identifying observational studies examining ATD use during the first trimester of pregnancy and risk of birth defects. Data were extracted on study characteristics, adjusted effect estimates and comparator groups. Effect estimates were pooled using a random-effects generic inverse variance method of analysis and absolute risk calculated.Results Seven cohort studies and one case–control study (involving 6212322 pregnancies and 388976 birth defects) were identified. Compared to unexposed women without hyperthyroidism, the association between ATD first trimester use and birth defects in offspring was: adjusted risk ratio [aRR] 1.16 95% CI 1.08-1.25 for propylthyoruacil (PTU); aRR 1.28 95% CI 1.06-1.54 for methimazole/carbimazole (MMI/CMZ); aRR 1.51, 95% CI 1.16-1.97 for both MMI/CMZ and PTU; and aRR 1.15 95%CI 1.02-1.29 for untreated hyperthyroidism. The risk of major birth defects per 1000 live births was: 9.6 for PTU; 16.8 for MMI/CMZ; 30.6 for both MMI/CMZ and PTU; and 9.0 for untreated hyperthyroidism.Conclusions When appropriately analysed this risk of birth defects associated with ATD use in the first trimester of pregnancy is attenuated. Although still elevated, the risk of birth defects is smallest with PTU compared to use of MMI/CMZ and may be similar to that of untreated hyperthyroidism.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://www.encepp.eu/encepp/viewResource.htm?id=30991 Funding StatementNo funding was obtained to conduct this study. H Nordeng is funded/ is supported by the European Research Council Starting Grant DrugsInPregnancy grant number 639377. DM is supported by a Wellcome Trust Clinical Research Development Fellowship (214588/Z/18/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approval was required to conduct this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is either contained within the manuscript or can be accessed via the referenced publications.